The Role of Inflammatory Biomarkers in Preventing Deep Sternal Wound Infections After Sternotomy

January 21, 2026 updated by: Levan Nebieridze
The goal of this observational study is to reveal blood biomarkers that will have prognostic significance in terms of the development of deep wound infection following sternotomy. As for the practical significance of the study, blood biomarkers correlated with deep wound infections can be used to prevent the development of wound infections in the postoperative period. Based on this, it is possible to formulate an algorithm for preventive measures.

Study Overview

Status

Active, not recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

30

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Georgia
      • Tbilisi, Georgia, 0119
        • Tbilisi State Medical University
      • Tbilisi, Georgia
        • Bokhua Memorial Cardiovascular Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

patients from Georgia, who undergo cardiac surgery operation

Description

Inclusion Criteria:

  • deep sternal wound infection

Exclusion Criteria:

  • bilateral internal thoracic artery graft

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
change in pre and postoperative inflammatory biomarker levels associated with development of deep sternal wound infection within 1 month
Time Frame: within 30 days after surgery
within 30 days after surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Levan Nebieridze

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 14, 2025

Primary Completion (Estimated)

September 4, 2026

Study Completion (Estimated)

April 14, 2028

Study Registration Dates

First Submitted

January 21, 2026

First Submitted That Met QC Criteria

January 21, 2026

First Posted (Actual)

January 29, 2026

Study Record Updates

Last Update Posted (Actual)

January 29, 2026

Last Update Submitted That Met QC Criteria

January 21, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • TbilisiSMU

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Diabete Mellitus

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Kingdom

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe